1. INTRODUCTION
Chemically, dapsone (4, 40 -diaminodiphenylsulfone, DDS) is an aniline derivative, a drug of the sulfone class.1 Dapsone is increasingly used in the treatment of a variety of dermatological disorders such as acne, dermatitis herpetiformis, psoriasis, and toxoplasma gondii infections and pneumocystis carinii pneumonia in acquired immunodeficiency syndrome (AIDS) patients and is drug of choice for leprosy commonly in combination with rifampicin and clofazimine in Nepal.1-2 DHS is a severe idiosyncratic drug reaction in response to dapsone characterised by the clinical symptoms of fever, skin eruption, and internal organ involvement (lung, liver, neurological, hematological and other systems) and DIH can be considered as one of the spectrum of DHS.2 In general, prevalence of DHS is 0.5-3%.2-4 Here we report a case who presented with fatigue, jaundice and mild upper abdominal pain 3 weeks after starting anti-leprosy drug regimen comprising dapsone.